Jump to Main Contents
研究所ロゴ

Home > Organization > Divisions and Independent Research Units > Cancer RNA Research Unit > Research Papers

Research Papers

(*equal contribution; #corresponding)

2024

  1. Kudo R, Safonov A, Jones C, Moiso E, Dry J R, Shao H, Nag S, Silva E M, Yildirim S Y, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, Bradic M, Fan L, Nakshatri H, Sudhan D R, Denz C R,  Reis-Filho J S, Goel S, Koff A, Weigelt B, Khan Q J, Razavi P, Chandarlapaty S. Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell.
    2024 Nov 11;42(11):1919-1935.e9. doi: 10.1016/j.ccell.2024.09.009. Epub 2024 Oct 10. PMID: 39393354
  2. Yano N, Pin Fee Chong P F, Kojima K K, Miyoshi T, Luqmen-Fatah A, Kimura Y, Kora K, Kayaki T, Maizuru K, Hayashi T, Yokoyama A, Ajiro M, Hagiwara M, Kondo T, Kira R, Takita J, Yoshida T. Long-read sequencing identifies an SVA_D retrotransposon insertion deep within the intron of ATP7A as a novel cause of occipital horn syndrome. J Med Genet. 2024 Sep 24;61(10):950-958. doi: 10.1136/jmg-2024-110056. PMID: 38960580.
  3. Jin Q, Harris E, Myers JA, Mehmood R, Cotton A, Shirnekhi HK, Baggett DW, Wen JQ, Schild AB, Bhansali RS, Klein J, Narina S, Pieters T, Yoshimi A, Pruett-Miller SM, Kriwacki R, Abdel-Wahab O, Malinge S, Ntziachristos P, Obeng EA, Crispino JD. Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia. Blood. 2024 Sep 24:blood.2024024281. doi: 10.1182/blood.2024024281. Online ahead of print. PMID: 39316649.
  4. Nishimura K, Takahara K, Komura K#, Ishida M, Hirosuna K, Maenosono R, Ajiro M, Sakamoto M, Iwatsuki K, Nakajima Y, Tsujino T, Taniguchi K, Tanaka T, Inamoto T, Hirose Y, Ono F, Kondo Y, Yoshimi A#, Azuma H. Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma. NPJ Precis Oncol. 2024 Sep 17;8(1):206. doi: 10.1038/s41698-024-00707-6. PMID: 39289546.
  5.  Kaito S, Aoyama K,  Oshima M, Tsuchiya A, Miyota M, Yamashita M, Koide S, Nakajima-Takagi Y, Kozuka-Hata H, Oyama M, Yabushita T, Ueno M, Hirao A, Tohyama K, Yamaguchi K, Furukawa Y, Kosako H, Goyama S, Yoshimi A, Nannya Y, Ogawa S, Agger K, Helin K,  Koseki H, Nishiyama A,  Nakanishi M, Iwama A. Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization. Nat Commun. 2024 Aug 28;15(1):7359.  doi: 10.1038/s41467-024-50498-4. PMID: 39198387.
  6. Mukohyama J, Koizumi M, Yamashita K, Yoshimi A, Shida D, Kakeji Y. Knockdown of CDX2 Induces microRNA-221 Up-regulation in Human Colon Cancer Cells. Anticancer Res. 2024 Aug;44(8):3553-3556. doi: 10.21873/anticanres.17177. PMID: 39060046
  7. Matsui S, Ri C, Bolanos L C, Choi K, Shibamiya A, Ishii A, Takaishi K, Oshima-Hasegawa N,  Tsukamoto S, Takeda Y, Mimura N, Yoshimi A, Yokote K, Starczynowski D T,  Sakaida E, Muto T. Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression. Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245-3. Online ahead of print. PMID: 38609495.
  8. Yamada M, Maeta K, Suzuki H, Kurosawa R, Takenouchi T, Awaya T, Ajiro M, Takeuchi A, Nishio,H, Hagiwara M, Miya F, Matsuo M, Kosaki K. Successful skipping of abnormal pseudoexon by antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated neurodegeneration. Sci Rep. 2024 Mar 18;14(1):6506. doi: 10.1038/s41598-024-56704-z. PMID: 38499569.

2023

  1. Ma HL, Bizet M, Soares Da Costa C, Murisier F, de Bony EJ, Wang MK, Yoshimi A, Lin KT, Riching KM, Wang X, Beckman JI, Arya S, Droin N, Calonne E, Hassabi B, Zhang QY, Li A, Putmans P, Malbec L, Hubert C, Lan J, Mies F, Yang Y, Solary E, Daniels DL, Gupta YK, Deplus R, Abdel-Wahab O, Yang YG, Fuks F. SRSF2 plays an unexpected role as reader of m5C on mRNA, linking epitranscriptomics to cancer. Mol Cell. 2023 Dec 7;83(23):4239-4254.e10. doi: 10.1016/j.molcel.2023.11.003. PMID: 38065062.
  2. Komura K#, Hirosuna K, Tokushige S, Nishimura K, Ishida M, Hayashi T, Ura A, Ohno T, Yamazaki S, Nakamori K, Kinoshita S, Tsujino T, Maenosono R, Ajiro M, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Konuma T, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A#, Azuma H. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer. Mol Cancer. 2023 Nov 18;22(1):185. doi: 10.1186/s12943-023-01897-6.PMID: 37980528.
  3. Kurosawa R, Iida K, Ajiro M, Awaya T, Yamada M, Kosaki K, Hagiwara M. PDIVAS: Pathogenicity predictor for Deep Intronic Variants causing Aberrant Splicing. BMC Genomics. 2023 Oct 10;24(1):601. doi: 10.1186/s12864-023-09645-2. PMID: 37817060.
  4. Muto T, Walker CS, Agarwal P, Vick E, Sampson A, Choi K, Niederkorn M, Ishikawa C, Hueneman K, Varney M, Starczynowski DT. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation. Haematologica. 2023 Oct 1;108(10):2715-2729. PMID: 37102608.
  5. Muto T. Role of innate immune signaling and inflammation in the pathogenesis of myeloid malignancies. Rinsho Ketsueki. 2023;64(9):962-969. doi: 10.11406/rinketsu.64.962. PMID: 37793872.
  6. Komura K#, Tokushige S, Ishida M, Hirosuna K, Yamazaki S, Nishimura K, Ajiro M, Ohno T, Nakamori K, Kinoshita S, Tsujino T, Maenosono R, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A#, Azuma H. Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab. Cancer Sci. 2023 Dec;114(12):4622-4631. doi: 10.1111/cas.15976. Epub 2023 Sep 26. PMID: 37752769. (#co-corresponding)
  7. Maenosono R. Sex difference and immunosenescence affect transplantation outcomes. Frontiers in Transplantation. 2023 Vol.2, DOI: 10.3389/frtra.2023.1235740.
  8. Yamauchi H, Momoki M, Kamiyama Y, Gunji T, Yokoyama H, Saito T, Boutboul D, Oksenhendler E, Yano S. Hodgkin Lymphoma-related Inflammatory Modification-displayed Castleman Disease-like Histological Features and Positron Emission Tomography/Computed Tomography Usefulness for the Differential Diagnosis: A Case Report. Intern Med.2024 Apr 1;63(7):993-998. doi: 10.2169/internalmedicine.2284-23. Epub 2023 Aug 9. PMID: 37558474.
  9. Shibamiya A, Miyamoto-Nagai Y, Koide S, Oshima M, Rizq O, Aoyama K, Nakajima-Takagi Y, Kato R, Kayamori K, Isshiki Y, Oshima-Hasegawa N, Muto T, Tsukamoto S, Takeda Y, Koyama-Nasu R, Chiba T, Honda H, Yokote K, Iwama A, Sakaida E, Mimura N. The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms. Cancer Immunol Immunother. 2023 Aug;72(8):2635-2648. doi: 10.1007/s00262-023-03447-x. Epub 2023 Apr 17. PMID: 37069353.
  10. Yoshida M, Yamauchi H, Sakumoto M, Yoshimi A#. [RNA splicing dysregulation in hematological malignancies]. Rinsho Ketsueki. 2023;64(7):646-653. doi: 10.11406/rinketsu.64.646. PMID: 37544725. (#corresponding)
  11. Igarashi T, Mazevet M, Yasuhara T, Yano K, Mochizuki A, Nishino M, Yoshida T, Yoshida Y, Takamatsu N, Yoshimi A, Shiraishi K, Horinouchi H, Kohno T, Hamamoto R, Adachi J, Zou L, Shiotani B. An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress. Nat Commun. 2023; 14(1):4991. doi: 10.1038/s41467-023-40578-2. PMID: 37591859.
  12. Yoshida M, Matsuda K, Taoka K, Honda A, Maki H, Masamoto Y, Jona M, Nishikawa M, Yatomi Y, Kurokawa M. Expansion of large granular lymphocytes after autologous hematopoietic stem cell transplantation. Int J Hematol. 2023 Jun;117(6):839-844. doi: 10.1007/s12185-023-03540-y. Epub 2023 Feb 11. PMID: 36773192.
  13. Muto T, Walker CS, Agarwal P, Vick E, Sampson A, Choi K, Niederkorn M, Ishikawa C, Hueneman K, Varney M, Starczynowski DT. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation. Haematologica. 2023 Oct 1;108(10):2715-2729. PMID: 37102608 

2022

  1. Shiraishi Y, Okada A, Chiba K, Kawachi A, Omori I, Mateos RN, Iida N, Yamauchi H, Kosaki K, Yoshimi A. Systematic identification of intron retention associated variants from massive publicly available transcriptome sequencing data. Nat Communs. 2022 Sep 29;13(1):5357. doi: 10.1038/s41467-022-32887-9. PMID: 36175409
  2. Hai Y, Kawachi A, He X, Yoshimi A#. Pathogenic roles of RNA-Binding Proteins in Sarcomas. Cancers. 2022 Aug 5;14(15):3812. doi: 10.3390/cancers14153812. PMID: 35954475. (#corresponding)
  3. Yamauchi H, Nishimura K, Yoshimi A#. Aberrant RNA splicing and therapeutic opportunities in cancers. Cancer Sci. 2022 Feb;113(2):373-381. doi: 10.1111/cas.15213. PMID: 34812550.
  4. Oishi A, Jockers R. Measuring Protein-Protein Interactions of Melatonin Receptors by Bioluminescence Resonance Energy Transfer (BRET). Methods Mol Biol. 2022;2550:207-218. doi: 10.1007/978-1-0716-2593-4_26. PMID: 36180695
  5. Oishi A, and Jockers R. Recent advances in orphan GPCRs research and therapeutic potential. GPCRs as Therapeutic Targets. 2022,1;20-59. doi: https://doi.org/10.1002/9781119564782.ch2

2021

  1. De Munck S, Provost M, Kurikawa M, Omori I, Mukohyama J, Felix J, Bloch Y, Abdel-Wahab O, Bazen F, Yoshimi A, Savvides SN. Structural basis of cytokine-mediated activation of ALK family receptors. Nature. 2021 Dec;600(7887):143-147. doi.org/10.1038/s41586-021-03959-5. PMID: 34646012
  2. Masashi M, Ito Y, Nakahara F, Hino T, Nakamura F, Iwasaki Y, Kawagoshi T, Koya J, Yoshimi A, Arai S, Kagoya Y, Kurokawa M. Efficient production of human neutrophils from iPSCs that prevent murine lethal infection with immune cell recruitment. Blood. 2021 Sep 29:blood.2021011576. doi: 10.1182/blood.2021011576. Online ahead of print. PMID: 34587247
  3. Honda A, Koya J, Yoshimi A, Miyauchi M, Taoka K, Kataoka K, Arai S, Kurokawa M. Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia. Exp Hematol. 2021 Jul 29:S0301-472X(21)00280-0. doi: 10.1016/j.exphem.2021.07.005. PMID: 34333045.
  4. Maki H, Yoshimi A, Shimada T, Arai S, Morita K, Kamikubo Y, Ikegawa M, Kurokawa M. Physical interaction between BAALC and DBN1 induces chemoresistance in leukemia. Exp Hematol. 2021 Feb;94:31-36. doi: 10.1016/j.exphem.2020.12.003. PMID: 33453340.

2020年

  1. Liu Z*, Yoshimi A*,#, Wang J, Cho H, Chun-Wei Lee S, Ki M, Bitner L, Chu T, Shah H, Liu B, Mato AR, Ruvolo P, Fabbri G, Pasqualucci L, Abdel-Wahab O, Rabadan R#. Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization. Cancer Discov. 2020 Jun;10(6):806-821. doi: 10.1158/2159-8290.CD-19-1330. PMID: 32188705. (*equal contribution; #co-corresponding)
  2. Yoshimi A, Trippett TM, Zhang N, Chen X, Penson AV, Arcila ME, Pichardo J, Baik J, Sigler A, Harada H, Fajgenbaum DC, Dogan A, Abdel-Wahab O, Xiao W. Genetic basis for iMCD-TAFRO. Oncogene. 2020 Apr;39(15):3218-3225. doi: 10.1038/s41388-020-1204-9. PMID: 32051554.
  3. Takaoka K, Koya J, Yoshimi A, Toya T, Kobayashi T, Nannya Y, Nakazaki K, Arai S, Ueno H, Usuki K, Yamashita T, Imanishi D, Sato S, Suzuki K, Harada H, Manabe A, Hayashi Y, Miyazaki Y, Kurokawa M. Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. Leuk Lymphoma. 2020 Mar 11;:1-7. doi: 10.1080/10428194.2020.1734595. PMID: 32157945.
  4. Yoshimi A. [Aberrant RNA splicing and development of hematological malignancies]. Rinsho Ketsueki. 2020;61(6):634-642. doi: 10.11406/rinketsu.61.634. PMID: 32624537.

2019年

  1. Yoshimi A*, Lin KT*, Wiseman DH*, Rahman MA, Pastore A, Wang B, Lee SC, Micol JB, Zhang XJ, de Botton S, Penard-Lacronique V, Stein EM, Cho H, Miles RE, Inoue D, Albrecht TR, Somervaille TCP, Batta K, Amaral F, Simeoni F, Wilks DP, Cargo C, Intlekofer AM, Levine RL, Dvinge H, Bradley RK, Wagner EJ, Krainer AR, Abdel-Wahab O. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019 Oct;574(7777):273-277. doi: 10.1038/s41586-019-1618-0. PMID: 31578525.
  2. Inoue D, Chew GL, Liu B, Michel BC, Pangallo J, D'Avino AR, Hitchman T, North K, Lee SC, Bitner L, Block A, Moore AR, Yoshimi A, Escobar-Hoyos L, Cho H, Penson A, Lu SX, Taylor J, Chen Y, Kadoch C, Abdel-Wahab O, Bradley RK. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019 Oct;574(7778):432-436. doi: 10.1038/s41586-019-1646-9. PMID: 31597964.
  3. Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX, Pastore A, Yoshimi A, Mandelker D, Ceyhan-Birsoy O, Ulaner GA, Walsh M, Yabe M, Petrova-Drus K, Arcila ME, Ladanyi M, Solit DB, Berger MF, Hyman DM, Lacouture ME, Erickson C, Saganty R, Ki M, Dunkel IJ, Santa-María López V, Mora J, Haroche J, Emile JF, Decaux O, Geissmann F, Savvides SN, Drilon A, Diamond EL, Abdel-Wahab O. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med. 2019 Dec;25(12):1839-1842. doi: 10.1038/s41591-019-0653-6. PMID: 31768065.
  4. Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, Gavrila EI, Stewart C, Melnik EM, Herrejon Chavez F, Bitner L, Yoshimi A, Lee SC, Inoue D, Liu B, Zhang XJ, Mato AR, Dogan A, Kharas MG, Chen Y, Wang D, Soni RK, Hendrickson RC, Prieto G, Rodriguez JA, Taylor BS, Abdel-Wahab O. Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. Cancer Discov. 2019 Oct;9(10):1452-1467. doi: 10.1158/2159-8290.CD-19-0298. PMID: 31285298.
  5. Wang E, Lu SX, Pastore A, Chen X, Imig J, Chun-Wei Lee S, Hockemeyer K, Ghebrechristos YE, Yoshimi A, Inoue D, Ki M, Cho H, Bitner L, Kloetgen A, Lin KT, Uehara T, Owa T, Tibes R, Krainer AR, Abdel-Wahab O, Aifantis I. Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer Cell. 2019 Mar 18;35(3):369-384.e7. doi: 10.1016/j.ccell.2019.01.010. PMID: 30799057.
  6. Takaoka K, Kawazu M, Koya J, Yoshimi A, Masamoto Y, Maki H, Toya T, Kobayashi T, Nannya Y, Arai S, Ueno T, Ueno H, Suzuki K, Harada H, Manabe A, Hayashi Y, Mano H, Kurokawa M. A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination. Leukemia. 2019 Jul;33(7):1773-1782. doi: 10.1038/s41375-019-0385-0. PMID: 30696947.

2018年

  1. Seiler M*, Yoshimi A*, Darman R*, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. PMID: 29457796.
  2. Yoshimi A, Abdel-Wahab O. Targeting mRNA Decapping in AML. Cancer Cell. 2018 Mar 12;33(3):339-341. doi: 10.1016/j.ccell.2018.02.015. PMID: 29533777.
  3. Lee SC, North K, Kim E, Jang E, Obeng E, Lu SX, Liu B, Inoue D, Yoshimi A, Ki M, Yeo M, Zhang XJ, Kim MK, Cho H, Chung YR, Taylor J, Durham BH, Kim YJ, Pastore A, Monette S, Palacino J, Seiler M, Buonamici S, Smith PG, Ebert BL, Bradley RK, Abdel-Wahab O. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell. 2018 Aug 13;34(2):225-241.e8. doi: 10.1016/j.ccell.2018.07.003. PMID: 30107174.
  4. Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. J Clin Invest. 2018 Aug 31;128(9):3819-3825. doi: 10.1172/JCI120787. PMID: 29920189.
  5. Fei DL, Zhen T, Durham B, Ferrarone J, Zhang T, Garrett L, Yoshimi A, Abdel-Wahab O, Bradley RK, Liu P, Varmus H. Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1. Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10437-E10446. doi: 10.1073/pnas.1812669115. PMID: 30322915.
  6. Cifani P, Dhabaria A, Chen Z, Yoshimi A, Kawaler E, Abdel-Wahab O, Poirier JT, Kentsis A. ProteomeGenerator: A Framework for Comprehensive Proteomics Based on de Novo Transcriptome Assembly and High-Accuracy Peptide Mass Spectral Matching. J Proteome Res. 2018 Nov 2;17(11):3681-3692. doi: 10.1021/acs.jproteome.8b00295. PMID: 30295032.
  7. Toya T, Ogura M, Toyama K, Yoshimi A, Shinozaki-Ushiku A, Honda A, Honda K, Hosoya N, Murakami Y, Kawashima H, Nannya Y, Arai S, Nakamura F, Shinoda Y, Nangaku M, Miyagawa K, Fukayama M, Moriya-Saito A, Katayama I, Ogura T, Kurokawa M. Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan. Haematologica. 2018 Nov;103(11):1815-1824. doi: 10.3324/haematol.2018.190728. PMID: 29976744.
  8. Taoka K, Arai S, Kataoka K, Hosoi M, Miyauchi M, Yamazaki S, Honda A, Aixinjueluo W, Kobayashi T, Kumano K, Yoshimi A, Otsu M, Niwa A, Nakahata T, Nakauchi H, Kurokawa M. Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. Sci Rep. 2018 Oct 26;8(1):15855. doi: 10.1038/s41598-018-34193-1. PMID: 30367142.
  9. Miyauchi M, Koya J, Arai S, Yamazaki S, Honda A, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M. ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells. Stem Cell Reports. 2018 Mar 13;10(3):1115-1130. doi: 10.1016/j.stemcr.2018.01.015. PMID: 29429960.

2017年

  1. Yoshimi A*, Balasis ME*, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017 Jul 27;130(4):397-407. doi: 10.1182/blood-2017-01-763219. PMID: 28576879.
  2. Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, Ng V, Xia B, Witkowski MT, Mitchell-Flack M, Grillo I, Bakogianni S, Ndiaye-Lobry D, Martín MT, Guillamot M, Banh RS, Xu M, Figueroa ME, Dickins RA, Abdel-Wahab O, Park CY, Tsirigos A, Neel BG, Aifantis I. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell. 2017 Sep 7;170(6):1079-1095.e20. doi: 10.1016/j.cell.2017.07.032. Epub 2017 Aug 17. PMID: 28823558.
  3. Yoshimi A, Abdel-Wahab O. Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins. Clin Cancer Res. 2017 Jan 15;23(2):336-341. doi: 10.1158/1078-0432.CCR-16-0131. PMID: 27836865. Review. 
  4. Yoshimi A, Abdel-Wahab O. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. Int J Hematol. 2017 Jun;105(6):720-731. doi: 10.1007/s12185-017-2242-0. PMID: 28466384. Review. 
  5. Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat Commun. 2017 May 18;8時15分429. doi: 10.1038/ncomms15429. PMID: 28516957.
  6. Durham BH, Roos-Weil D, Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, Papo M, Hélias-Rodzewicz Z, Terrones N, Ozkaya N, Dogan A, Rampal R, Urbain F, Le Fèvre L, Diamond EL, Park CY, Papo T, Charlotte F, Gorochov G, Taly V, Bernard OA, Amoura Z, Abdel-Wahab O, Lemoine FM, Haroche J, Emile JF. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood. 2017 Jul 13;130(2):176-180. doi: 10.1182/blood-2016-12-757377. PMID: 28566492.

2016年

  1. Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, Nakajima H, Hayashi Y, Takahashi T, Moriya-Saito A, Suzuki K, Harada H, Komatsu N, Usuki K, Ichikawa M, Kurokawa M. Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. Ann Oncol. 2016 May;27(5):887-95. doi: 10.1093/annonc/mdw066. PMID: 26884589.
  2. Yoshimi A, Abdel-Wahab O. Defining risk in MDS over time. Blood. 2016 Aug 18;128(7):885-6. doi: 10.1182/blood-2016-07-724930. PMID: 27539994.
  3. Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016 Jun;22(6):672-8. doi: 10.1038/nm.4097. PMID: 27135740.
  4. Masamoto Y, Arai S, Sato T, Yoshimi A, Kubota N, Takamoto I, Iwakura Y, Yoshimura A, Kadowaki T, Kurokawa M. Adiponectin Enhances Antibacterial Activity of Hematopoietic Cells by Suppressing Bone Marrow Inflammation. Immunity. 2016 Jun 21;44(6):1422-33. doi: 10.1016/j.immuni.2016.05.010. PMID: 27317261.
  5. Sakurai M, Kasahara H, Yoshida K, Yoshimi A, Kunimoto H, Watanabe N, Shiraishi Y, Chiba K, Tanaka H, Harada Y, Harada H, Kawakita T, Kurokawa M, Miyano S, Takahashi S, Ogawa S, Okamoto S, Nakajima H. Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele. Blood Cancer J. 2016 Feb 5;6:e392. doi: 10.1038/bcj.2015.81. PMID: 26849013.
  6. Yamamoto H, Lu J, Oba S, Kawamata T, Yoshimi A, Kurosaki N, Yokoyama K, Matsushita H, Kurokawa M, Tojo A, Ando K, Morishita K, Katagiri K, Kotani A. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target. Sci Rep. 2016 Jan 12. doi: 10.1038/srep19204. PMID: 26754824.

2015年

  1. Kogure Y, Yoshimi A, Ueda K, Nannya Y, Ichikawa M, Nakamura F, Kurokawa M. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis. Ann Hematol. 2015 Jun;94(6):989-94. doi: 10.1007/s00277-015-2309-z. PMID: 25687839.
  2. Uni M, Yoshimi A, Yamazaki S, Taoka K, Shinohara A, Nannya Y, Nakamura F, Kurokawa M. Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia. Jpn J Clin Oncol. 2015 Aug;45(8):745-8. doi: 10.1093/jjco/hyv071. PMID: 25989991.
  3. Iizuka H, Kagoya Y, Kataoka K, Yoshimi A, Miyauchi M, Taoka K, Kumano K, Yamamoto T, Hotta A, Arai S, Kurokawa M. Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Exp Hematol. 2015 Oct;43(10):849-57. doi: 10.1016/j.exphem.2015.05.004. PMID: 26021490.

2014年

  1. Yoshimi A, Toya T, Kawazu M, Ueno T, Tsukamoto A, Iizuka H, Nakagawa M, Nannya Y, Arai S, Harada H, Usuki K, Hayashi Y, Ito E, Kirito K, Nakajima H, Ichikawa M, Mano H, Kurokawa M. Recurrent CDC25C mutations drive malignant transformation in FPD/AML. Nat Commun. 2014 Aug 27. doi: 10.1038/ncomms5770. PMID: 25159113.
  2. Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, Kobayashi H, Saito T, Iwakura Y, Kurokawa M. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. J Clin Invest. 2014 Feb;124(2):528-42. doi: 10.1172/JCI68101. PMID: 24382349.
  3. Kagoya Y, Yoshimi A, Tsuruta-Kishino T, Arai S, Satoh T, Akira S, Kurokawa M. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. Blood. 2014 Nov 6;124(19):2996-3006. doi: 10.1182/blood-2014-04-570572. PMID: 25217696.
  4. Ueda K, Yoshimi A, Kagoya Y, Nishikawa S, Marquez VE, Nakagawa M, Kurokawa M. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16. Cancer Sci. 2014 May;105(5):512-9. doi: 10.1111/cas.12386. PMID: 24612037.
  5. Yoshimi A, Kurokawa M. [Development of molecular targeted therapy for hematological disorder in the era of genomic drug discovery]. Nihon Rinsho. 2014 Jun;72(6):1005-11. PMID: 25016796. Review. 
  6. Yoshimi A, Kurokawa M. [Leukemia stem cell and clonal evolution]. Nihon Rinsho. 2014 Jun;72(6):1012-7. PMID: 25016797. Review. 
  7. Honda A, Yoshimi A, Ushiku T, Shinoda Y, Kawano H, Toya T, Kogure Y, Yamashita H, Kume H, Nannya Y, Kurokawa M. Successful Control of Carcinoma of Unknown Primary with Axitinib, a Novel Molecular-Targeted Agent: A Case Report. Chemotherapy. 2014;60(5-6):342-5. doi: 10.1159/000437135. PMID: 26288144.
  8. Hangai S, Yoshimi A, Hosoi A, Matsusaka K, Ichikawa M, Fukayama M, Kurokawa M. An indeterminate result of QuantiFERON-TB Gold In-Tube for miliary tuberculosis due to a high level of IFN-γ production. Int J Hematol. 2014 Apr;99(4):523-6. doi: 10.1007/s12185-014-1504-3. PMID: 24481938.
  9. Toya T, Yoshimi A, Morioka T, Arai S, Ichikawa M, Usuki K, Kurokawa M. Development of hairy cell leukemia in familial platelet disorder with predisposition to acute myeloid leukemia. Platelets. 2014;25(4):300-2. doi: 10.3109月09日537104.2013.818636. PMID: 23971860.
  10. Yamazaki S, Nakamura F, Yoshimi A, Ichikawa M, Nannya Y, Kurokawa M. Safety of high-dose micafungin for patients with hematological diseases. Leuk Lymphoma. 2014 Nov;55(11):2572-6. doi: 10.3109月10日428194.2014.885514. PMID: 24460099.
  11. Uni M, Nakamura F, Yoshimi A, Shinozaki-Ushiku A, Hosoi A, Nakazaki K, Nannya Y, Fukayama M, Kurokawa M. Transformation of follicular lymphoma in the retroperitoneal muscles demonstrated by CT-guided needle biopsy of FDG-avid lesions; case series. Int J Clin Exp Pathol. 2014;7(1):402-6. eCollection 2014. PMID: 24427363.
  12. Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, Nukina A, Kumagai K, Kubota N, Nakagawa M, Arai S, Yoshimi A, Honda H, Kadowaki T, Kurokawa M. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Oncogene. 2014 Oct 16;33(42):5028-38. doi: 10.1038/onc.2014.108. PMID: 24747972.
  13. Harada S, Yamazaki S, Nakamura F, Morita K, Yoshimi A, Shinozaki-Ushiku A, Fukayama M, Kurokawa M. Autoimmune neutropenia preceding Helicobacter pylori-negative MALT lymphoma with nodal dissemination. Int J Clin Exp Pathol. 2014;7(9):6386-90. eCollection 2014. PMID: 25337296.
  14. Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S, Fukayama M. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene. 2014 May 8;33(19):2454-63. doi: 10.1038/onc.2013.204. PMID: 23752186.
  15. Nukina A, Kagoya Y, Watanabe-Okochi N, Arai S, Ueda K, Yoshimi A, Nannya Y, Kurokawa M. Single-cell gene expression analysis reveals clonal architecture of blast-phase chronic myeloid leukaemia. Br J Haematol. 2014 May;165(3):414-6. doi: 10.1111/bjh.12726. PMID: 24401018.

2013年

  1. Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A, Tsuruta T, Masuda A, Yokota H, Yatomi Y, Takahashi K, Kitaura J, Kitamura T, Kurokawa M. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model. Blood. 2013 May 16;121(20):4142-55. doi: 10.1182/blood-2011-07-368654. PMID: 23547050.
  2. Morita K, Yoshimi A, Masuda A, Ichikawa M, Yatomi Y, Kurokawa M. Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion. Int J Hematol. 2013 Aug;98(2):247-9. doi: 10.1007/s12185-013-1372-2. PMID: 23743950.
  3. Uni M, Yoshimi A, Nakamura F, Takazawa Y, Fukayama M, Kurokawa M. Successful allogeneic stem cell transplantation for Lennert lymphoma. Ann Hematol. 2013 Jun;92(6):859-60. doi: 10.1007/s00277-012-1642-8. PMID: 23224245.
  4. Ichikawa M, Yoshimi A, Nakagawa M, Nishimoto N, Watanabe-Okochi N, Kurokawa M. A role for RUNX1 in hematopoiesis and myeloid leukemia. Int J Hematol. 2013 Jun;97(6):726-34. doi: 10.1007/s12185-013-1347-3. PMID: 23613270. Review. 
  5. Uni M, Yoshimi A, Maki H, Maeda D, Nakazaki K, Nakamura F, Fukayama M, Kurokawa M. Successful treatment with recombinant thrombomodulin for B-cell lymphoma-associated hemophagocytic syndrome complicated by disseminated intravascular coagulation. Int J Clin Exp Pathol. 2013;6(6):1190-4. PMID: 23696942.
  6. Iizuka H, Yoshimi A, Yamamoto G, Masuda A, Nannya Y, Ichikawa M, Yatomi Y, Kurokawa M. Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia. Rinsho Ketsueki. 2013 May;54(5):468-72. PMID: 23727686.
  7. Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A, Tsuruta T, Masuda A, Yokota H, Yatomi Y, Takahashi K, Kitaura J, Kitamura T, Kurokawa M. [The shortest isoform of C/EBPβ, Liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model]. Rinsho Ketsueki. 2013 Aug;54(8):749-58. PMID: 24005435.

2012年

  1. Yoshimi A, Yamamoto G, Goto T, Koike K, Kurokawa M. Hepatocellular carcinoma in cirrhotic liver with graft-versus-host disease. Ann Hematol. 2012 Sep;91(9):1501-2. doi: 10.1007/s00277-012-1416-3. PMID: 22314841.
  2. Miyauchi M, Yoshimi A, Nannya Y, Takazawa Y, Ichikawa M, Fukayama M, Kurokawa M. Efficacy of pleural biopsy for diagnosis of pleural effusion due to chronic GVHD after hematopoietic stem cell transplantation. Int J Hematol. 2012 Jul;96(1):146-8. doi: 10.1007/s12185-012-1110-1. PMID: 22684925.

2011年

  1. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, Kurokawa M. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood. 2011 Mar 31;117(13):3617-28. doi: 10.1182/blood-2009-12-261602. PMID: 21289308.
  2. Yoshimi A, Kurokawa M. Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget. 2011 Jul;2(7):575-86. doi: 10.18632/oncotarget.304. PMID: 21795762. Review. 
  3. Yoshimi A, Kurokawa M. Key roles of histone methyltransferase and demethylase in leukemogenesis. J Cell Biochem. 2011 Feb;112(2):415-24. doi: 10.1002/jcb.22972. PMID: 21268062. Review. 
  4. Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, Goyama S, Kurokawa M. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood. 2011 Jun 9;117(23):6304-14. doi: 10.1182/blood-2009-07-234310. PMID: 21190993.
  5. Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, Shimabe M, Arai S, Nakagawa M, Imai Y, Kumano K, Kumagai K, Kubota N, Kadowaki T, Kurokawa M. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 2011 Nov 21;208(12):2403-16. doi: 10.1084/jem.20110447. PMID: 22084405.
  6. Nakagawa M, Shimabe M, Watanabe-Okochi N, Arai S, Yoshimi A, Shinohara A, Nishimoto N, Kataoka K, Sato T, Kumano K, Nannya Y, Ichikawa M, Imai Y, Kurokawa M. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors. Blood. 2011 Dec 15;118(25):6626-37. doi: 10.1182/blood-2010-12-326710. PMID: 22021368.
  7. Sugaya M, Fujita H, Izutsu K, Oshima K, Takazawa Y, Ohmatsu H, Yoshimi A, Takahashi T, Kanda Y, Kurokawa M, Tamaki K, Sato S. Primary cutaneous anaplastic large cell lymphoma with leg involvement: a case report and review of 11 cases. J Dermatol. 2011 Oct;38(10):1009-12. doi: 10.1111/j.1346-8138.2010.01150.x. PMID: 21434982.

2009年

  1. Yoshimi A, Takahashi T, Motokura T, Yatomi Y, Chiba S, Kurokawa M. Hemoperitoneum due to spontaneous rupture of the left gastroepiploic artery in a patient with hemophilia A. Ann Hematol. 2009 Aug;88(8):811-2. doi: 10.1007/s00277-008-0664-8. PMID: 19093114.
  2. Yoshimi A, Nannya Y, Ueda K, Asano D, Yamamoto G, Kumano K, Hangaishi A, Matsui Y, Takahashi T, Imai Y, Sugawara Y, Kokudo N, Kurokawa M. Successful hematopoietic stem cell transplantation from an HLA-identical sibling in a patient with aplastic anemia after HLA-haploidentical living-related liver transplantation for fulminant hepatitis. Biol Blood Marrow Transplant. 2009 Mar;15(3):389-90. doi: 10.1016/j.bbmt.2008.11.021. PMID: 19203732.
  3. Yoshimi A, Asai T, Maeda D, Hangaishi A, Sakatani T, Takahashi T, Imai Y, Fukayama M, Kurokawa M. Chronic myelomonocytic leukemia presenting severe uterine hemorrhage due to uterine infiltration of leukemic cells and early-stage endometrial adenocarcinoma. Arch Gynecol Obstet. 2009 Dec;280(6):1077-8. doi: 10.1007/s00404-009-1086-0. PMID: 19381665.
  4. Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y, Kurokawa M. Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene. 2009 Dec 10;28(49):4364-74. doi: 10.1038/onc.2009.288. PMID: 19767769.

2008年

  1. Yoshimi A, Nannya Y, Sakata-Yanagimoto M, Oshima K, Takahashi T, Kanda Y, Motokura T, Chiba S, Kurokawa M. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation. Am J Hematol. 2008 Aug;83(8):635-9. doi: 10.1002/ajh.21208. PMID: 18506704.
  2. Yoshimi A, Izutsu K, Takahashi M, Kako S, Oshima K, Kanda Y, Motokura T, Chiba S, Momose T, Ohtomo K, Kurokawa M. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Am J Hematol. 2008 Jun;83(6):477-81. doi: 10.1002/ajh.21158. PMID: 18266206.
  3. Yoshimi A, Asai T, Hangaishi A, Takahashi T, Chiba S, Kurokawa M. Hemorrhagic cystitis in a patient receiving gemtuzumab ozogamicin for relapsed acute promyelocytic leukemia after cord blood transplantation. Ann Hematol. 2008 Oct;87(10):851-2. doi: 10.1007/s00277-008-0482-z. PMID: 18386004.
  4. Yoshimi A, Kumano K, Motokura T, Takazawa Y, Oota S, Chiba S, Takahashi T, Fukayama M, Kurokawa M. ESHAP therapy effective in a patient with Langerhans cell sarcoma. Int J Hematol. 2008 Jun;87(5):532-537. doi: 10.1007/s12185-008-0075-6. PMID: 18415657.
  • Our Research Focus